Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04308681 · ClinicalTrials.gov registry record · Phase 2
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 403
- Enrollment target
NCT04308681 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 403 participants.
The verdict
NCT04308681, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 403 participants
- Enrollment target
Study Summary
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
Interventions
- DRUG BMS-986278
- OTHER BMS-986278 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2023-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04308681
The ClinicalTrials.gov registry entry for NCT04308681 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986278 is the first listed.
NCT04308681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04308681 about?
NCT04308681 is a clinical study titled "A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis". The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
What is the current status of trial NCT04308681?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 403 participants. The study started on 2020-07-29. Estimated completion is 2023-09-22.
What interventions are being tested in trial NCT04308681?
The interventions under investigation include: BMS-986278 (DRUG), BMS-986278 Placebo (OTHER).
Who is sponsoring clinical trial NCT04308681?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.